A client reported blood in the urine and muscle soreness three months after starting atorvastatin. How should the nurse respond?

When a client reports blood in the urine and muscle soreness, it raises significant concerns, particularly in relation to potential serious adverse effects linked to atorvastatin. This medication is known for its role in managing cholesterol levels, but it can also lead to conditions such as rhabdomyolysis, which can result in muscle damage and consequently lead to the presence of myoglobin in the urine, potentially causing hematuria (blood in the urine).

Stopping atorvastatin immediately is critical in this scenario to prevent any further complications or severe muscle-related issues, given the symptoms presented. The recommendation to seek immediate medical evaluation at the clinic the next morning emphasizes the necessity for further assessment, including blood tests to evaluate kidney function and muscle enzyme levels.

Responding with the suggestion to continue taking atorvastatin or downplaying the severity of the symptoms does not adequately address the patient’s reported signs, which could indicate serious health risks. Therefore, advising the patient to halt the medication and seek medical attention shows a proper understanding of the potential implications of these symptoms and prioritizes the client's safety.